Click for best price

Next Generation Cancer Diagnostics Market Size, Share 2022

Market Analysis and Insights: Global Next Generation Cancer Diagnostics Market

The global Next Generation Cancer Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Next Generation Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Next Generation Cancer Diagnostics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Next Generation Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Next Generation Cancer Diagnostics market.

Global Next Generation Cancer Diagnostics Scope and Market Size

Next Generation Cancer Diagnostics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Next Generation Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2030.

Segment by Type

Next Generation Sequencing

qPCR & Multiplexing

DNA Microarrays

Others

Segment by Application

Hospitals

Clinics

Others

By Region

North America

United States

Canada

Europe

Germany

France

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Cepheid

Koninklijke Philips N.V

F. Hoffmann-La Roche Ltd

Qiagen

Novartis AG

Abbott

Thermo Fisher Scientific

Opko Health

Myriad Genetics

Agilent Technologies

GE Healthcare

PerkinElmer

Genomic Health

Illumina

Hologic

Almac Group

Janssen Global Services

Sysmex Corporation

The information for each competitor/Company Profile includes:

Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Next Generation Cancer Diagnostics product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Next Generation Cancer Diagnostics, with price, sales, revenue, and global market share of Next Generation Cancer Diagnostics from 2019 to 2022.

Chapter 3, the Next Generation Cancer Diagnostics competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Next Generation Cancer Diagnostics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Next Generation Cancer Diagnostics market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Next Generation Cancer Diagnostics.

Chapter 13, 14, and 15, to describe Next Generation Cancer Diagnostics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

Estimates 2022-2027 2021-2025 Next Generation Cancer Diagnostics Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
Market dynamics scenario, along with growth opportunities of the market in the years to come
Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes	Report Details
Report Title	Global Next Generation Cancer Diagnostics Market Research Report 2023
Historical Year	2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year	2021
Forecast Year	2029
Number of Pages	104 Pages
Customization Available	Yes, the report can be customized as per your need.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2017 VS 2021 VS 2030
1.2.2 Next Generation Sequencing
1.2.3 qPCR & Multiplexing
1.2.4 DNA Microarrays
1.2.5 Others
1.3 Market by Application
1.3.1 Global Next Generation Cancer Diagnostics Market Share by Application: 2017 VS 2021 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Cancer Diagnostics Market Perspective (2017-2030)
2.2 Next Generation Cancer Diagnostics Growth Trends by Region
2.2.1 Next Generation Cancer Diagnostics Market Size by Region: 2017 VS 2021 VS 2030
2.2.2 Next Generation Cancer Diagnostics Historic Market Size by Region (2017-2023)
2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Region (2023-2030)
2.3 Next Generation Cancer Diagnostics Market Dynamics
2.3.1 Next Generation Cancer Diagnostics Industry Trends
2.3.2 Next Generation Cancer Diagnostics Market Drivers
2.3.3 Next Generation Cancer Diagnostics Market Challenges
2.3.4 Next Generation Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2017-2023)
3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2017-2023)
3.2 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
3.4 Global Next Generation Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2021
3.5 Next Generation Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Next Generation Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Next Generation Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Cancer Diagnostics Breakdown Data by Type
4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2017-2023)
4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2023-2030)
5 Next Generation Cancer Diagnostics Breakdown Data by Application
5.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2017-2023)
5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Next Generation Cancer Diagnostics Market Size (2017-2030)
6.2 North America Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
6.3 North America Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Next Generation Cancer Diagnostics Market Size (2017-2030)
7.2 Europe Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
7.3 Europe Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2017-2030)
8.2 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
8.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Next Generation Cancer Diagnostics Market Size (2017-2030)
9.2 Latin America Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
9.3 Latin America Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2017-2030)
10.2 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
10.3 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Cepheid
11.1.1 Cepheid Company Detail
11.1.2 Cepheid Business Overview
11.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
11.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.1.5 Cepheid Recent Development
11.2 Koninklijke Philips N.V
11.2.1 Koninklijke Philips N.V Company Detail
11.2.2 Koninklijke Philips N.V Business Overview
11.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
11.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.2.5 Koninklijke Philips N.V Recent Development
11.3 F. Hoffmann-La Roche Ltd
11.3.1 F. Hoffmann-La Roche Ltd Company Detail
11.3.2 F. Hoffmann-La Roche Ltd Business Overview
11.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
11.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.3.5 F. Hoffmann-La Roche Ltd Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Detail
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
11.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.4.5 Qiagen Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
11.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.5.5 Novartis AG Recent Development
11.6 Abbott
11.6.1 Abbott Company Detail
11.6.2 Abbott Business Overview
11.6.3 Abbott Next Generation Cancer Diagnostics Introduction
11.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
11.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Opko Health
11.8.1 Opko Health Company Detail
11.8.2 Opko Health Business Overview
11.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
11.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.8.5 Opko Health Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Detail
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
11.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.9.5 Myriad Genetics Recent Development
11.10 Agilent Technologies
11.10.1 Agilent Technologies Company Detail
11.10.2 Agilent Technologies Business Overview
11.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
11.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.10.5 Agilent Technologies Recent Development
11.11 GE Healthcare
11.11.1 GE Healthcare Company Detail
11.11.2 GE Healthcare Business Overview
11.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
11.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.11.5 GE Healthcare Recent Development
11.12 PerkinElmer
11.12.1 PerkinElmer Company Detail
11.12.2 PerkinElmer Business Overview
11.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
11.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.12.5 PerkinElmer Recent Development
11.13 Genomic Health
11.13.1 Genomic Health Company Detail
11.13.2 Genomic Health Business Overview
11.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
11.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.13.5 Genomic Health Recent Development
11.14 Illumina
11.14.1 Illumina Company Detail
11.14.2 Illumina Business Overview
11.14.3 Illumina Next Generation Cancer Diagnostics Introduction
11.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.14.5 Illumina Recent Development
11.15 Hologic
11.15.1 Hologic Company Detail
11.15.2 Hologic Business Overview
11.15.3 Hologic Next Generation Cancer Diagnostics Introduction
11.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.15.5 Hologic Recent Development
11.16 Almac Group
11.16.1 Almac Group Company Detail
11.16.2 Almac Group Business Overview
11.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
11.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.16.5 Almac Group Recent Development
11.17 Janssen Global Services
11.17.1 Janssen Global Services Company Detail
11.17.2 Janssen Global Services Business Overview
11.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
11.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.17.5 Janssen Global Services Recent Development
11.18 Sysmex Corporation
11.18.1 Sysmex Corporation Company Detail
11.18.2 Sysmex Corporation Business Overview
11.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
11.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.18.5 Sysmex Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2030
Table 2. Key Players of Next Generation Sequencing
Table 3. Key Players of qPCR & Multiplexing
Table 4. Key Players of DNA Microarrays
Table 5. Key Players of Others
Table 6. Global Next Generation Cancer Diagnostics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2030
Table 7. Global Next Generation Cancer Diagnostics Market Size by Region (US$ Million): 2017 VS 2021 VS 2030
Table 8. Global Next Generation Cancer Diagnostics Market Size by Region (2017-2023) & (US$ Million)
Table 9. Global Next Generation Cancer Diagnostics Market Share by Region (2017-2023)
Table 10. Global Next Generation Cancer Diagnostics Forecasted Market Size by Region (2023-2030) & (US$ Million)
Table 11. Global Next Generation Cancer Diagnostics Market Share by Region (2023-2030)
Table 12. Next Generation Cancer Diagnostics Market Trends
Table 13. Next Generation Cancer Diagnostics Market Drivers
Table 14. Next Generation Cancer Diagnostics Market Challenges
Table 15. Next Generation Cancer Diagnostics Market Restraints
Table 16. Global Next Generation Cancer Diagnostics Revenue by Players (2017-2023) & (US$ Million)
Table 17. Global Next Generation Cancer Diagnostics Market Share by Players (2017-2023)
Table 18. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2021)
Table 19. Ranking of Global Top Next Generation Cancer Diagnostics Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Next Generation Cancer Diagnostics Revenue (CR5 and HHI) & (2017-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Next Generation Cancer Diagnostics Product Solution and Service
Table 23. Date of Enter into Next Generation Cancer Diagnostics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next Generation Cancer Diagnostics Market Size by Type (2017-2023) & (US$ Million)
Table 26. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2017-2023)
Table 27. Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2023-2030) & (US$ Million)
Table 28. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2023-2030)
Table 29. Global Next Generation Cancer Diagnostics Market Size by Application (2017-2023) & (US$ Million)
Table 30. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2017-2023)
Table 31. Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2023-2030) & (US$ Million)
Table 32. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2023-2030)
Table 33. North America Next Generation Cancer Diagnostics Market Size by Country (2017-2023) & (US$ Million)
Table 34. North America Next Generation Cancer Diagnostics Market Size by Country (2023-2030) & (US$ Million)
Table 35. Europe Next Generation Cancer Diagnostics Market Size by Country (2017-2023) & (US$ Million)
Table 36. Europe Next Generation Cancer Diagnostics Market Size by Country (2023-2030) & (US$ Million)
Table 37. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2017-2023) & (US$ Million)
Table 38. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2023-2030) & (US$ Million)
Table 39. Latin America Next Generation Cancer Diagnostics Market Size by Country (2017-2023) & (US$ Million)
Table 40. Latin America Next Generation Cancer Diagnostics Market Size by Country (2023-2030) & (US$ Million)
Table 41. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2017-2023) & (US$ Million)
Table 42. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2023-2030) & (US$ Million)
Table 43. Cepheid Company Detail
Table 44. Cepheid Business Overview
Table 45. Cepheid Next Generation Cancer Diagnostics Product
Table 46. Cepheid Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 47. Cepheid Recent Development
Table 48. Koninklijke Philips N.V Company Detail
Table 49. Koninklijke Philips N.V Business Overview
Table 50. Koninklijke Philips N.V Next Generation Cancer Diagnostics Product
Table 51. Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 52. Koninklijke Philips N.V Recent Development
Table 53. F. Hoffmann-La Roche Ltd Company Detail
Table 54. F. Hoffmann-La Roche Ltd Business Overview
Table 55. F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Product
Table 56. F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 57. F. Hoffmann-La Roche Ltd Recent Development
Table 58. Qiagen Company Detail
Table 59. Qiagen Business Overview
Table 60. Qiagen Next Generation Cancer Diagnostics Product
Table 61. Qiagen Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 62. Qiagen Recent Development
Table 63. Novartis AG Company Detail
Table 64. Novartis AG Business Overview
Table 65. Novartis AG Next Generation Cancer Diagnostics Product
Table 66. Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 67. Novartis AG Recent Development
Table 68. Abbott Company Detail
Table 69. Abbott Business Overview
Table 70. Abbott Next Generation Cancer Diagnostics Product
Table 71. Abbott Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 72. Abbott Recent Development
Table 73. Thermo Fisher Scientific Company Detail
Table 74. Thermo Fisher Scientific Business Overview
Table 75. Thermo Fisher Scientific Next Generation Cancer Diagnostics Product
Table 76. Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 77. Thermo Fisher Scientific Recent Development
Table 78. Opko Health Company Detail
Table 79. Opko Health Business Overview
Table 80. Opko Health Next Generation Cancer Diagnostics Product
Table 81. Opko Health Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 82. Opko Health Recent Development
Table 83. Myriad Genetics Company Detail
Table 84. Myriad Genetics Business Overview
Table 85. Myriad Genetics Next Generation Cancer Diagnostics Product
Table 86. Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 87. Myriad Genetics Recent Development
Table 88. Agilent Technologies Company Detail
Table 89. Agilent Technologies Business Overview
Table 90. Agilent Technologies Next Generation Cancer Diagnostics Product
Table 91. Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 92. Agilent Technologies Recent Development
Table 93. GE Healthcare Company Detail
Table 94. GE Healthcare Business Overview
Table 95. GE Healthcare Next Generation Cancer DiagnosticsProduct
Table 96. GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 97. GE Healthcare Recent Development
Table 98. PerkinElmer Company Detail
Table 99. PerkinElmer Business Overview
Table 100. PerkinElmer Next Generation Cancer DiagnosticsProduct
Table 101. PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 102. PerkinElmer Recent Development
Table 103. Genomic Health Company Detail
Table 104. Genomic Health Business Overview
Table 105. Genomic Health Next Generation Cancer DiagnosticsProduct
Table 106. Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 107. Genomic Health Recent Development
Table 108. Illumina Company Detail
Table 109. Illumina Business Overview
Table 110. Illumina Next Generation Cancer DiagnosticsProduct
Table 111. Illumina Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 112. Illumina Recent Development
Table 113. Hologic Company Detail
Table 114. Hologic Business Overview
Table 115. Hologic Next Generation Cancer DiagnosticsProduct
Table 116. Hologic Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 117. Hologic Recent Development
Table 118. Almac Group Company Detail
Table 119. Almac Group Business Overview
Table 120. Almac Group Next Generation Cancer DiagnosticsProduct
Table 121. Almac Group Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 122. Almac Group Recent Development
Table 123. Janssen Global Services Company Detail
Table 124. Janssen Global Services Business Overview
Table 125. Janssen Global Services Next Generation Cancer DiagnosticsProduct
Table 126. Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 127. Janssen Global Services Recent Development
Table 128. Sysmex Corporation Company Detail
Table 129. Sysmex Corporation Business Overview
Table 130. Sysmex Corporation Next Generation Cancer DiagnosticsProduct
Table 131. Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2017-2023) & (US$ Million)
Table 132. Sysmex Corporation Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next Generation Cancer Diagnostics Market Share by Type: 2021 VS 2030
Figure 2. Next Generation Sequencing Features
Figure 3. qPCR & Multiplexing Features
Figure 4. DNA Microarrays Features
Figure 5. Others Features
Figure 6. Global Next Generation Cancer Diagnostics Market Share by Application in 2021 & 2030
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Next Generation Cancer Diagnostics Report Years Considered
Figure 11. Global Next Generation Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2017-2030
Figure 12. Global Next Generation Cancer Diagnostics Market Size, (US$ Million), 2017 VS 2021 VS 2030
Figure 13. Global Next Generation Cancer Diagnostics Market Share by Region: 2021 VS 2030
Figure 14. Global Next Generation Cancer Diagnostics Market Share by Players in 2021
Figure 15. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Next Generation Cancer Diagnostics Revenue in 2021
Figure 17. North America Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 18. North America Next Generation Cancer Diagnostics Market Share by Country (2017-2030)
Figure 19. United States Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 20. Canada Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 21. Europe Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 22. Europe Next Generation Cancer Diagnostics Market Share by Country (2017-2030)
Figure 23. Germany Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 24. France Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 25. U.K. Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 26. Italy Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 27. Russia Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 28. Nordic Countries Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 29. Asia-Pacific Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 30. Asia-Pacific Next Generation Cancer Diagnostics Market Share by Region (2017-2030)
Figure 31. China Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 32. Japan Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 33. South Korea Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 34. Southeast Asia Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 35. India Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 36. Australia Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 37. Latin America Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 38. Latin America Next Generation Cancer Diagnostics Market Share by Country (2017-2030)
Figure 39. Mexico Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 40. Brazil Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 41. Middle East & Africa Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 42. Middle East & Africa Next Generation Cancer Diagnostics Market Share by Country (2017-2030)
Figure 43. Turkey Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 44. Saudi Arabia Next Generation Cancer Diagnostics Market Size YoY Growth (2017-2030) & (US$ Million)
Figure 45. Cepheid Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 46. Koninklijke Philips N.V Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 47. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 48. Qiagen Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 49. Novartis AG Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 50. Abbott Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 51. Thermo Fisher Scientific Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 52. Opko Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 53. Myriad Genetics Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 54. Agilent Technologies Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 55. GE Healthcare Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 56. PerkinElmer Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 57. Genomic Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 58. Illumina Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 59. Hologic Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 60. Almac Group Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 61. Janssen Global Services Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 62. Sysmex Corporation Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2017-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

DOWNLOAD SAMPLE

Download
Free Sample

Request
Customization

Check
Discount

REPORT PURCHASE OPTIONS

Single User Price : $2762

Multi User Price : $4143

Enterprise Price : $5524

---- OR ----

Frequently Asked Questions ?

Delivery Time

Upto 24 hrs - Working days
Upto 48 hrs max - Weekends and public holidays

User License

Single User License
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

Multi user License
A license granted to multiple users.

Site License
A license granted to a single business site/establishment.

Corporate License, Global License
A license granted to all employees within organisation access to the product.

Payment Options

Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer

Report Delivery

Email
Hard Copy

Our Key Features

Data Accuracy and Reliability
Data Security
Customized Research
Trustworthy
Competitive Offerings

Global Next Generation Cancer Diagnostics Market Research Report 2023